Does Rallies show 13F holders for MIST?

Yes. Rallies tracks hedge fund and 13F ownership data for MIST, including fund names, share counts, latest tracked quarter, and position changes when available.

Is MIST research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MIST. It does not provide personalized investment advice.

MIST (Milestone Pharmaceuticals Inc. Common Shares) Stock Analysis - Hedge Fund Holdings

Milestone Pharmaceuticals Inc. Common Shares (MIST) is a publicly traded Healthcare sector company. As of May 21, 2026, MIST trades at $1.44 with a market cap of $181.77M and a P/E ratio of -2.00. MIST moved +4.90% today. Year to date, MIST is -25.74%; over the trailing twelve months it is +7.91%. Its 52-week range spans $0.63 to $3.06. Analyst consensus is strong buy with an average price target of $7.25. Rallies surfaces MIST's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns MIST stock?

Hedge funds tracked by Rallies that own MIST include Orbimed Advisors. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Milestone Pharmaceuticals Inc. Common Shares.

MIST Key Metrics

Key financial metrics for MIST
Metric	Value
Price	$1.44
Market Cap	$181.77M
P/E Ratio	-2.00
EPS	$-0.75
Dividend Yield	0.00%
52-Week High	$3.06
52-Week Low	$0.63
Volume	14
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-63.06M
Gross Margin	0.00%

Top Hedge Funds Holding MIST

Orbimed Advisors holds 3.22M shares of MIST, changed +61.09% as of Sep 30, 2025.

Latest MIST News

Milestone Pharmaceuticals Posts $26.1M Q1 Loss, $238K CARDAMYST Revenue — May 13, 2026
Milestone Pharmaceuticals Shares Plunge After Q1 CARDAMYST Revenue Misses Forecast — May 13, 2026
Milestone Pharmaceuticals Posts $0.2M Q1 Sales, $184M Cash Runway — May 13, 2026
Milestone Launches Phase 4 PSVT Registry to Enroll 450 Patients Across 20 Sites — Apr 10, 2026
Milestone’s CARDAMYST Added to Express Scripts National Formularies Effective March 27, 2026 — Mar 31, 2026

Recent MIST Insider Trades

Oliveto Joseph sold 36.50K (~$82.49K) on Apr 16, 2026.
Bharucha David sold 12.24K (~$23.63K) on Jan 26, 2026.
Nelson Jeffrey Edward sold 12.24K (~$23.63K) on Jan 26, 2026.

MIST Analyst Consensus

4 analysts cover MIST: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.25.

Common questions about MIST

Who owns MIST stock?: Hedge funds tracked by Rallies that own MIST include Orbimed Advisors. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Milestone Pharmaceuticals Inc. Common Shares.
Does Rallies show 13F holders for MIST?: Yes. Rallies tracks hedge fund and 13F ownership data for MIST, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MIST research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MIST. It does not provide personalized investment advice.